Placebo News and Research

RSS

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Individual variation in viral dynamics could underlie inconsistencies in COVID-19 antiviral treatments

Due to variation in viral dynamics between people, improving the experimental design could help develop effective antiviral treatments for COVID-19.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Repurposing existing medications to reduce the severity of sleep apnea

In an Australian world-first, researchers have successfully repurposed two existing medications to reduce the severity of sleep apnea in people by at least 30 per cent.

2 Jul 2021

High omega 3 diet associated with reduction of headaches

Eating a diet rich in omega 3 (n-3) fatty acids reduces the frequency of headaches compared with a diet with normal intake of omega 3 and omega 6 (n-6) fatty acids, finds a study published by The BMJ today.

2 Jul 2021

Prenatal THC and CBD exposure impairs offspring's ability to respond to fluoxetine

Scientists at Indiana University have found that significant amounts of the two main components of cannabis, THC and CBD, enter the embryonic brain of mice in utero and impair the mice's ability as adults to respond to fluoxetine, a drug commonly used to treat anxiety and depression and known by the brand name Prozac.

1 Jul 2021

Strength training for breathing muscles lowers blood pressure, improves vascular health

Working out just five minutes daily via a practice described as "strength training for your breathing muscles" lowers blood pressure and improves some measures of vascular health as well as, or even more than, aerobic exercise or medication, new CU Boulder research shows.

30 Jun 2021

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

Tackling emerging SARS-CoV-2 variants

An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines’, which presents global strategies for the possible escape from vaccine-elicited immunity.

29 Jun 2021

Metabolic activators can reduce recovery time in patients with mild-to-moderate Covid-19

Metabolic activators were found to reduce recovery time by as many as 3.5 days in patients with mild-to-moderate Covid-19, according to a Swedish-British study published today in Advanced Science.

28 Jun 2021

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

Oncotarget published "Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib" which reported that this study investigated the association of the IGF/CTP score with overall survival and progression-free survival of HCC patients treated with sorafenib.

28 Jun 2021

An oral pill for COVID-19? Molnupiravir shows promise

Recently, researchers reported molnupiravir as the first oral and direct-acting antiviral that is highly effective at reducing SARS-CoV-2 levels.

27 Jun 2021

Many people with fibromyalgia substitute CBD for opioids and pain medications, finds study

Fibromyalgia is one of many chronic pain conditions that remains stubbornly difficult to treat.

24 Jun 2021

A study on hospitalized COVID-19 patients who received plasma therapy

A new study has been published which focuses on the evaluation of the outcomes of infected COVID-19 patients who were treated with CCP therapy.

23 Jun 2021

Study determines the mechanism behind respiratory inflammation and finds effective treatment

Applied Biological Laboratories (Applied Bio), a biopharmaceutical company focused on the respiratory disease market, announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta(TM), a 100% naturally derived, over-the-counter (OTC) drug for cold, cough and sore throat.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Investigational Alzheimer's drug reduces molecular markers of the disease

An investigational Alzheimer's drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU).

21 Jun 2021

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Globally, an estimated 10 million people develop tuberculosis (TB) each year and the disease remains a leading cause of death from a single infectious agent. Standard short-course anti-TB treatment still requires a regimen of at least six months of antimicrobial drugs, and drug-resistant TB is an increasing public health threat.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Placebo News and Research

Antibiotic clofoctol shows potential against SARS-CoV-2

Individual variation in viral dynamics could underlie inconsistencies in COVID-19 antiviral treatments

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Repurposing existing medications to reduce the severity of sleep apnea

High omega 3 diet associated with reduction of headaches

Prenatal THC and CBD exposure impairs offspring's ability to respond to fluoxetine

Strength training for breathing muscles lowers blood pressure, improves vascular health

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

Tackling emerging SARS-CoV-2 variants

Metabolic activators can reduce recovery time in patients with mild-to-moderate Covid-19

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

An oral pill for COVID-19? Molnupiravir shows promise

Many people with fibromyalgia substitute CBD for opioids and pain medications, finds study

A study on hospitalized COVID-19 patients who received plasma therapy

Study determines the mechanism behind respiratory inflammation and finds effective treatment

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Investigational Alzheimer's drug reduces molecular markers of the disease

Combination of doxycycline and TB drug treatment reduces the size of lung cavities

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News